Background: Interventions for aortic aneurysm sac growth have been reported across multiple time points after endovascular aortic aneurysm repair (EVAR). We report the long-term outcomes of patients after EVAR monitored with duplex ultrasound (DUS) imaging with respect to the need for and type of intervention after 5 years.
Endovascular aortic aneurysm repair (EVAR) has become the standard treatment for abdominal aortic aneurysms. 1, 2 Other reports estimate that 9% to 18% of patients will require a secondary procedure after EVAR at a mean of 23 months, but the need for interventions after longer periods of graft surveillance is poorly defined. [3] [4] [5] Methods for EVAR surveillance include computed tomography angiography (CTA) and duplex ultrasound (DUS) imaging. Our preference and that of others is DUS imaging, given lower costs and decreased radiation exposure. [6] [7] [8] We report the long-term fate of patients after EVAR monitored with DUS imaging for >5 years with respect to the need for and type of intervention.
METHODS
We reviewed records of all patients who underwent EVAR between January 1, 1998, and December 31, 2010, at Pennsylvania Hospital (Philadelphia, Pa) and Danbury Hospital (Danbury, Conn). Patient data were entered into computerized registries at each institution. Only patients who underwent DUS surveillance for >5 years after EVAR were included in the study. We excluded patients who were lost to follow-up or died before the 5-year minimum follow-up. All patients who missed a follow-up appointment were contacted by phone call by the office, and a letter was mailed. This study used deidentified patient data, informed consent was waived, and Institutional Review Board approval was waived at both institutions. Our routine surveillance program included DUS imaging #1 month of EVAR, 6 months later, and then annually if the studies showed no abnormalities. Indications for CTA or arteriography and intervention included type I or III endoleak, sac diameter enlargement of >5 mm, threatened or occluded graft limb, and rupture. Of Table I .
Of the 156 patients monitored with DUS imaging for >5 years, 44 patients (28%) required an intervention during follow-up: 35 (22%) for endoleak and nine (6%) for a failing or failed graft limb (Table II) . Subsequent aneurysm rupture occurred in four of these 44 patients.
First reintervention #5 years after EVAR. The first reintervention was performed in 34 of the 156 patients (22%) #5 years of stent graft insertion for endoleak in 25 patients (13 patients required multiple procedures) or for limb stenosis (n ¼ 5) or occlusion (n ¼ 4) in nine patients. A rupture occurred in four of the 25 patients with endoleak who underwent a first reintervention #5 years. The known incidence of rupture was 2.6% (4 of 156).
Patients without rupture underwent an average of 1.79 interventions (range, 1-3) per patient for endoleak. This compares to an average of 3.0 interventions (range, 1-4) per patient in the ruptured group.
Interventions were performed for failing (n ¼ 5) or failed (n ¼ 4) limbs in nine patients, all within the first 5 years after EVAR. Graft limb stenosis developed in five patients, who were treated from 1 month to 4 years postoperatively. Limb occlusion developed in four patients: 1 required a femoral-femoral bypass after 1 month, 1 underwent graft limb thrombectomy, followed by kissing stents after 4 months, 1 underwent an axillofemoral bypass after 13 months, and 1 had iliac stent placement at 2 years that eventually required an axillary-bifemoral bypass after 5 years.
Ruptured aneurysms after EVAR. As mentioned, rupture occurred in four of the 156 patients (2.6%). Two of the four patients survived repair of their rupture. Patient 1 was compliant with all routine postoperative DUS assessments, which showed no evidence of sac growth or endoleak. She presented to the emergency department with a rupture from a type II endoleak 2.5 years after EVAR that was treated with suture ligation of the feeding lumbar vessel after opening the aneurysm sac. She survived and remained compliant with her follow-up.
Patient 2 died of a rupture. He underwent three reinterventions for type Ib endoleak within the first 5 years postoperatively. The fatal rupture occurred 1 year after his last intervention, with the interval finding of a minimal increase in sac size on DUS imaging. Although an open repair was recommended after his type Ib endoleak recurred the first time, the patient refused to undergo an open procedure.
Patient 3 ruptured 11 years post-EVAR after two reinterventions for a type II endoleak at 1 and 7 years post-EVAR and one proximal cuff extension for a type I endoleak 7 years after implantation. He then was treated for a rupture at another hospital and survived. He was not fully compliant with his follow-up after his proximal extension, but the few DUS assessments he had showed no evidence of sac growth.
Patient 4 ruptured 12 years post-EVAR after four reinterventions for a type I endoleak. An open procedure was recommended after two interventions for type I endoleak, but the patient refused. He was monitored closely for 10 years and then missed two DUS assessments and visits. He then presented 2 years later, when the aneurysm ruptured, and he ultimately died after attempted surgical repair.
All of the patients had an increase in sac size documented by DUS imaging (or CT) in advance of rupture; however, this was not always immediately before the rupture.
First reintervention after 5 years post-EVAR. Ten of the 156 patients (6%) monitored with DUS imaging for >5 years after EVAR underwent a first reintervention >5 years after EVAR (all for endoleaks and none for limb stenosis or occlusion): 3 type I, 2 type II with sac expansion, 2 type III, 2 with combined type I and II, and 1 with an unknown type of endoleak (treated by relining of the graft). No ruptures occurred in patients who underwent their first reintervention after 5 years. Endograft device. AneuRx (Medtronic, Minneapolis, Minn) was the most commonly placed endograft in this series of 156 patients monitored for >5 years after EVAR with DUS imaging (Table III) . Conclusions on the propensity for endoleak based on the type of stent graft cannot be drawn from this data set because more challenging cases, such as aneurysms with shorter or more angulated necks, were treated with different grafts according to surgeon preference.
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DISCUSSION
The Society for Vascular Surgery Practice Guidelines recommended lifelong EVAR surveillance. 2 However, few studies report a large number of patients monitored >5 years. Warner and colleagues questioned the SVS recommendation, noting only 2% (1 of 58) of their patients required a first reintervention after 5 years. 9 In our series, with approximately three times as many patients, we documented that 6% (10 of 146) required a first intervention >5 years after EVAR despite no abnormalities on prior DUS studies. We also documented that fully 28% (44 of 156) of patients monitored for a mean of 7.5 years with DUS imaging after EVAR required an intervention at some point during follow-up. Our results show a greater frequency of reintervention after EVAR than other reports with shorter follow-up, in which the incidence was only w15%.
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Our study further emphasizes the need for continued long-term follow-up of EVAR patients. Based on these data and the Society for Vascular Surgery recommendations, we recommend annual surveillance in all EVAR patients (without complications) because our data have demonstrated that endoleaks can occur even after a long period of normal US results. We recommend increasing this frequency after a patient has a complication (including endoleak or other intervention) until several normal US studies have been documented.
Endoleaks are the most common complication after EVAR. An analysis of endoleaks in the Veterans Affair Open vs Endovascular Repair (OVER) Trial of Abdominal Aortic Aneurysms found that endoleaks, mostly type II, developed in 30%, but not all of these patients underwent intervention. 11 This group found that patients who developed type II endoleaks >1 year after the procedure were more likely to experience sac growth, but longterm follow-up was limited. In our study, >50% of the EVAR grafts placed are no longer available on the market. Although Ancure (Guidant, Indianapolis, Ind) and AneuRx have a trend toward more endoleaks in this study, there was more limited data about these grafts available in the patients treated in the late 1990s and early 2000s. These patients should continue to have annual surveillance because of the risk of late complications >5 years that we have demonstrated. A limitation of our study was the poor compliance with follow-up, which is a dilemma at many institutions. Wu et al 12 found that only 47% of their patients were 13 When comparing the number of complications between the compliant and noncompliant groups, they found that the patients who were fully compliant with graft surveillance studies had an increased number of complications compared with patients who were contacted by phone calls but refused to return for followup studies. 13 The reason for this confounding finding is unclear, and we do not believe that their results justify stopping EVAR surveillance. Indeed, the highest-risk patients may have undergone the most intense surveillance. Compliance with follow-up remains a frustrating problem despite a concerted effort on behalf of the physicians and office staff to insure adequate follow-up. The results of our study, in which only 34% of our patients were monitored for >5, years despite our repeated and emphatic recommendations to return for DUS surveillance, were almost identical to those of the EUROSTAR registry. Not all patients who do not have long-term follow-up may be strictly lost to follow-up. A number of these patients may have also followed up at other institutions.
Finally, this retrospective review does not accurately capture the overall mortality rate of the 456 EVAR patients. The rupture rate may be higher than reported because some patients with rupture may have gone to other hospitals.
CONCLUSIONS
In our series of patients monitored with DUS imaging for >5 years after EVAR, intervention was required in 28% of patients during follow-up. Although limb occlusion did not occur after 5 years in these 156 patients, 6% required intervention for a new endoleak after 5 years, despite prior normal results on follow-up DUS studies. Therefore, lifelong surveillance should continue to be emphasized to EVAR patients. Likewise, vascular surgeons need to continue to search for means to improve patient compliance with EVAR surveillance, although whether this effort will result in decreased long-term adverse consequences has not been proven. 
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